HUTCHMED (China) Ltd (HCM) research

HUTCHMED (China) Ltd
ShareXLinkedInReddit
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Last price
$14.07
As of

HUTCHMED (China) Ltd (HCM): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-03.

As of . Source: SEC EDGAR filings for HCM. Method and limitations.

SHARE THIS CARD

Share the HCM intelligence card

A branded snapshot of HCM: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion HCM intelligence card preview
Post to X
LIVE TERMINAL

See HCM live in the terminal

Track HCM's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live HCM terminal, free

Active signals for HCM

FREE, NO ACCOUNT

Every signal on HCM, as it fires

You are seeing 5 of 8 signals recorded on HCM since 2026-05-27.

The five above landed across 3 days. The other 3 were recorded on those same days. 4 of the 8 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in HCM (2026Q2)

Manager / securityMarket value% portfolioQoQ
RENAISSANCE TECHNOLOGIES LLCCUSIP 44842L103 · 2026Q2$1.4M0.00%,
TWO SIGMA INVESTMENTS, LPCUSIP 44842L103 · 2026Q2$681K0.00%,
CITADEL ADVISORS LLCCUSIP 44842L103 · 2026Q2$410K0.00%,
MILLENNIUM MANAGEMENT LLCCUSIP 44842L103 · 2026Q2$284K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, HCM

HCM against its peers

HCM's operating margin of -7.1% ranks in the 39th percentile of 18 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-05-31.

MetricHCMPeer medianPercentilen
Revenue FY549M USD632M USD4518
Revenue YoY-13.0%n/an/a4
Gross marginn/a49.3%n/a16
Operating margin-7.1%-0.7%3918
Net margin83.3%-6.4%9819
Return on equity36.9%-13.7%9716

Peers (21): CURLF, PBH, ALVO, RGC, PRGO, ETON, GTBIF, INDV, HROW, CRON, KNSA, TLRY, VREOF, AQST, ELAN, EOLS, KMDA, TKNO, NIKA, VRNO, CGC. Left out: HYPMY (no annual filing), RDY (period gap), EVO (period gap), SGIOF (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (HCM: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more HCM signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to HCMand get the insider, 13F, options, and confluence read in one view.

Open the live HCM terminal, free